US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Vaccinex, Inc. - Common Stock (NQ:VCNX)

1.410 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.410
Bid (Size) 1.320 (1)
Ask (Size) 1.460 (2)
Prev. Close 1.410
Today's Range 1.410 - 1.410
52wk Range N/A - N/A
Shares Outstanding 65,941,086
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
This first-in-class differentiated approach will be highlighted during a Featured Research Session entitled Alzheimer's therapy: mechanisms beyond amyloid 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports 2025 Annual Financial Results
From Vaccinex, Inc.
Via GlobeNewswire

Performance

More News

Read More
News headline image
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024 ↗
Via InvestorPlace
News headline image
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? ↗
Via Benzinga
News headline image
Crude Oil Down Over 1%; US Industrial Production Declines In November ↗
Via Benzinga
News headline image
Dow Dips Over 200 Points; US Retail Sales Top Estimates ↗
Via Benzinga
Topics Stocks
News headline image
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
What's Going On With Vaccinex Stock Wednesday? ↗
Via Benzinga
News headline image
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Around $3M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Via Benzinga

Frequently Asked Questions

Is Vaccinex, Inc. - Common Stock publicly traded?
Yes, Vaccinex, Inc. - Common Stock is publicly traded.
What exchange does Vaccinex, Inc. - Common Stock trade on?
Vaccinex, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vaccinex, Inc. - Common Stock?
The ticker symbol for Vaccinex, Inc. - Common Stock is VCNX on the Nasdaq Stock Market
What is the current price of Vaccinex, Inc. - Common Stock?
The current price of Vaccinex, Inc. - Common Stock is 1.410
When was Vaccinex, Inc. - Common Stock last traded?
The last trade of Vaccinex, Inc. - Common Stock was at 12/17/24 04:00 PM ET
What is the market capitalization of Vaccinex, Inc. - Common Stock?
The market capitalization of Vaccinex, Inc. - Common Stock is 92.98M
How many shares of Vaccinex, Inc. - Common Stock are outstanding?
Vaccinex, Inc. - Common Stock has 93M shares outstanding.